Skip to content
2000
image of Navigating Regulatory Complexities in Biosimilar Approvals and Imports for Autoimmune Disorder Management: A Comparative Analysis of FDA (US), EMA (EU), and CDSCO (India) Guidelines

Abstract

Biosimilars offer cost-effective alternatives for autoimmune disorder treatment. However, India’s stringent regulatory barriers, including mandatory local trials, unclear interchangeability guidelines, and strict pricing controls, hinder market access. This study conducts a comparative analysis of the FDA (US), EMA (EU), and CDSCO (India) regulatory frameworks, highlighting key differences in approval pathways, post-marketing surveillance, and import regulations. Unlike previous studies, this paper employs a structured SWOT analysis to assess the impact of India's regulatory landscape on biosimilar accessibility. The findings reveal that India's local clinical trial mandates and complex approval processes hinder biosimilar adoption despite prior FDA or EMA approvals. Additionally, the absence of interchangeability guidelines discourages physician confidence, while stringent pricing policies under the Drug Price Control Order (DPCO) reduce manufacturer incentives. To improve biosimilar market penetration, India must streamline regulatory approvals, harmonize clinical trial requirements with international standards, and establish clear interchangeability guidelines. These reforms are essential to enhance the affordability and accessibility of biosimilars in the management of autoimmune disorders.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raddf/10.2174/0126673878360952250715031025
2025-08-01
2025-11-17

  • From This Site

    /content/journals/raddf/10.2174/0126673878360952250715031025
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Davis A.A. Patel V.G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer 2019 7 1 278 10.1186/s40425‑019‑0768‑9 31655605
    [Google Scholar]
  2. Naci H. Davis C. Savović J. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis. BMJ 2019 366 l5221 10.1136/bmj.l5221 31533922
    [Google Scholar]
  3. Agbogbo F.K. Ecker D.M. Farrand A. Current perspectives on biosimilars. J. Ind. Microbiol. Biotechnol. 2019 46 9-10 1297 1311 10.1007/s10295‑019‑02216‑z 31317293
    [Google Scholar]
  4. Panda T. Lala P.K. Manoharan K. Jinson J. George M. Evaluation of the current status of ethics committees in India using the National Accreditation Board for Hospitals and Health-care Providers, central drugs standard control organization (CDSCO), and department of health research databases. Perspect. Clin. Res. 2024 16 2 75 80 10.4103/picr.picr_40_24
    [Google Scholar]
  5. Shenoy S.R. Contributions of Department of Biotechnology to non-communicable disease biology research in India. Curr. Sci. 2022 123 2 148 10.18520/cs/v123/i2/148‑153
    [Google Scholar]
  6. Rani A. Shukla V.K. Impact of rules for new drug and clinical trial in India. Int J Drug Regul Aff 2020 8 1 25 30
    [Google Scholar]
  7. O’Callaghan J. Barry S.P. Bermingham M. Morris J.M. Griffin B.T. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur. J. Clin. Pharmacol. 2019 75 1 1 11 30187103
    [Google Scholar]
  8. Hasnan N.Z. Basha R.K. Amin N.A. Ramli S.H. Tang J.Y. Ab Aziz N. Analysis of the most frequent nonconformance aspects related to good manufacturing practices (GMP) among small and medium enterprises (SMEs) in the food industry and their main factors. Food Cont 2022 141 109205 10.1016/j.foodcont.2022.109205
    [Google Scholar]
  9. Alomar M. Tawfiq A.M. Hassan N. Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther. Adv. Drug Saf. 2020 11 2042098620938595 32843958
    [Google Scholar]
  10. Shim S.B. Choi C.W. Shin J.H. Report on the seventh meeting of national control laboratories for vaccines and biologicals of the WHO Western Pacific and South-East Asia member states. Biologicals 2023 84 101712 37797484
    [Google Scholar]
  11. Selvaraj S. Farooqui H.H. Mehta A. Mathur M.R. Evaluating the impact of price regulation (Drug Price Control Order 2013) on antibiotic sales in India: a quasi-experimental analysis, 2008-2018. J. Pharm. Policy Pract. 2022 15 1 68 36273222
    [Google Scholar]
  12. Rajput H. Raikwar M.A. Regulatory authority and government policies. the center for drug evaluation and research uses different requirements for the three main drug product. IOSR J. Pharm. 2024 14 1 42 50
    [Google Scholar]
  13. Charoenwong B. Kwan A. Umar T. Does regulatory jurisdiction affect the quality of investment-adviser regulation? Am. Econ. Rev. 2019 109 10 3681 3712
    [Google Scholar]
  14. Jois R. Mukherjee S. Rajeswari S. Rath P.D. Goyal V. Gupta D. Similar biologics in India: A story of access or excess regulation? Indian J. Med. Res. 2020 152 5 456 467 10.4103/ijmr.IJMR_43_18
    [Google Scholar]
  15. Williams T. An evaluation of the biologics price competition and innovation act and its impact on innovation in the pharmaceutical industry. 2022. Available from: Williams, Tara and Miao, Qing, An Evaluation of the Biologics Price Competition and Innovation Act and its Impact on Innovation in the Pharmaceutical Industry (May 15, 2022). Available at SSRN: https://ssrn.com/abstract=4194903 or 10.2139/ssrn.4194903
  16. Teixeira T. Kweder S.L. Saint-Raymond A. Are the european medicines agency, US food and drug administration, and other international regulators talking to each other? Clin. Pharmacol. Ther. 2020 107 3 507 513 31449664
    [Google Scholar]
  17. Subbiah V. The next generation of evidence-based medicine. Nat. Med. 2023 29 1 49 58 36646803
    [Google Scholar]
  18. Shenoy S.R. Dey B. Funding for cancer research by an Indian funding agency, DBT. J. Biosci. 2021 46 1 2 33576340
    [Google Scholar]
  19. Beringer P. Winter’s basic clinical pharmacokinetics. Philadelphia, PA: 2023
    [Google Scholar]
  20. Thigpen J.C. Odle B.L. Harirforoosh S. Opioids: a review of pharmacokinetics and pharmacodynamics in neonates, infants, and children. Eur. J. Drug Metab. Pharmacokinet. 2019 44 5 591 609 31006834
    [Google Scholar]
  21. Afzali A. Furtner D. Melsheimer R. Molloy P.J. The automatic substitution of biosimilars: definitions of interchangeability are not interchangeable. Adv. Ther. 2021 38 5 2077 2093 33745111
    [Google Scholar]
  22. Le Flohic E. Vrijens B. Hiligsmann M. The impacts of undetected nonadherence in phase II, III and post-marketing clinical trials: An overview. Br. J. Clin. Pharmacol. 2024 90 8 1984 2003 38752447
    [Google Scholar]
  23. Rajesh D. Thejaswini M. Drug safety alerts issued by the National Coordination Centre for Pharmacovigilance Programme of India: current practices and future recommendations. Asian J Pharm Res Health Care 2023 15 1 64 69
    [Google Scholar]
  24. Prakash J. Sachdeva R. Shrivastava T.P. Jayachandran C.V. Sahu A. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India. Indian J. Pharmacol. 2021 53 2 143 152 34100398
    [Google Scholar]
  25. Potter R.A. Bending the rules: procedural politicking in the bureaucracy. Chicago, IL University of Chicago Press 2019 10.7208/chicago/9780226621883.001.0001
    [Google Scholar]
  26. Porter G. Kotwani A. Bhullar L. Joshi J. Over-the-counter sales of antibiotics for human use in India: The challenges and opportunities for regulation. Med. Law Int. 2021 21 2 147 173 10.1177/09685332211020786
    [Google Scholar]
  27. Mondal D. Chakrabarti K. Banerjee S. Lal D.D. Publication output with citation-based performance of selected DBT institutes in India. DESIDOC J. Libr. Inf. Technol. 2021 41 2 157 165 10.14429/djlit.41.02.16547
    [Google Scholar]
  28. Rezaie J. Feghhi M. Etemadi T. A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun. Signal. 2022 20 1 145 10.1186/s12964‑022‑00959‑4 36123730
    [Google Scholar]
  29. Basak P. Abir T. Al Mamun A. A global study on the correlates of gross domestic product (GDP) and COVID-19 vaccine distribution. Vaccines 2022 10 2 266 10.3390/vaccines10020266 35214724
    [Google Scholar]
  30. Vončina L. Strbad T. Fürst J. Pricing and reimbursement of patent-protected medicines: challenges and lessons from South-Eastern Europe. Appl. Health Econ. Health Policy 2021 19 6 915 927 10.1007/s40258‑021‑00678‑w 34553334
    [Google Scholar]
  31. Gafforov M. Akromaliyev O. Digitalization of customs duties. Bullet Sci Pract 2021 7 4 353 356 10.33619/2414‑2948/65/42
    [Google Scholar]
  32. Tecante K.E. Sokija A. The periodic safety update report and post-market surveillance report under the new EU Medical Device Regulation. Med. Writ. 2022 31 50 55
    [Google Scholar]
  33. Steinberg J.R. Turner B.E. Weeks B.T. Analysis of female enrollment and participant sex by burden of disease in US clinical trials between 2000 and 2020. JAMA Netw. Open 2021 4 6 2113749 34143192
    [Google Scholar]
  34. Allen H.J. Regulatory sandboxes. George Washington Law Rev. 2019 87 579
    [Google Scholar]
  35. Druedahl L.C. Kälvemark Sporrong S. Minssen T. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution. PLoS One 2022 17 1 0262537 35015783
    [Google Scholar]
  36. Wintoki M.B. Xi Y. Friendly directors and the cost of regulatory compliance. J. Corp. Finance 2019 58 112 141 10.1016/j.jcorpfin.2019.04.011
    [Google Scholar]
  37. Gallego G. Topaloglu H. Revenue management and pricing analytics. New York, NY Springer 2019
    [Google Scholar]
  38. Paul P Kapur R Mittra S Shah N Rao GK Erick ME Umesh S Athalye SN Increasing adoption of qualityassured biosimilars to address access challenges in low- and middle-income countries. Generics and Biosimilars Initiative Journal (GaBI Journal). 2024 13 2 40 54 10.5639/gabij.2024.1302.008
    [Google Scholar]
  39. Malipatil N.B. Haridas K.M. Shruthi D.P. Biosimilars and Regulations: A Review. J. Pharm. Biomed. Sci. 2015 05 06 453 468
    [Google Scholar]
  40. Marne Minal S. Ijppr. Human, 2020 Vol. 18 4 51 64
    [Google Scholar]
  41. Diana Varghese Shayma Karbelkar Smrithi Ravikumar Monica Jadhav Vikram Gota (2021) Current State of Regulatory Oversight of Biosimilars in India and Its Implications on the Quality of Drugs: A Comparative Assessment with EU and FDA Regulations. Journal of Biotechnology & Bioinformatics Research. SRC/JBBR-141 10.47363/JBBR/2021(3)140
    [Google Scholar]
/content/journals/raddf/10.2174/0126673878360952250715031025
Loading
Navigating Regulatory Complexities in Biosimilar Approvals and Imports for Autoimmune Disorder Management: A Comparative Analysis of FDA (US), EMA (EU), and CDSCO (India) Guidelines
Bentham Science Publishers ; https://doi.org/10.2174/0126673878360952250715031025
/content/journals/raddf/10.2174/0126673878360952250715031025
/content/journals/raddf/10.2174/0126673878360952250715031025
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: regulatory challenges ; biologics ; interchangeability ; Biosimilars ; autoimmune disorders ; food and drug administration ; importation ; european medicines agency ; approval process ; central drugs standard control organization ; clinical trials

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test